Relation of omega-3 fatty acid and C-reactive protein to peripheral artery disease in patients with coronary artery disease

详细信息    查看全文

• 作者：Tsuyoshi Sugiura (1)
  Daiji Yoshikawa (2)
  Hideki Ishii (2)
  Susumu Suzuki (2)
  Soichiro Kumagai (2)
  Yosuke Inoue (2)
  Satoshi Okumura (2)
  Satoshi Isobe (2)
  Mutsuharu Hayashi (2)
  Hirohiko Ando (3)
  Tetsuya Amano (3)
  Toyoaki Murohara (2)
  
• 关键词：Eicosapentaenoic acid ; Docosahexaenoic acid ; Ankle ; brachial pressure index ; C ; reactive protein
• 刊名：Heart and Vessels
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：29
• 期：4
• 页码：449-455
• 全文大小：298 KB
• 参考文献：1. Kromhout D, Bosschieter EB, de Lezenne Coulander C (1985) The inverse relation between fish consumption and 20-year mortality from coronary heart disease. N Engl J Med 312:1205-209 CrossRef
  2. Albert CM, Hennekens CH, O’Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE (1998) Fish consumption and risk of sudden cardiac death. JAMA 279:23-8. http://jama.jamanetwork.com/article.aspx?articleid=185895#qundefined
  3. Rissanen T, Voutilainen S, Nyyssonen K, Lakka TA, Salonen JT (2000) Fish oil-derived fatty acids, docosahexaenoic acid and docosapentaenoic acid, and the risk of acute coronary events: the Kuopio ischaemic heart disease risk factor study. Circulation 102:2677-679 CrossRef
  4. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K (2007) Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369:1090-098 CrossRef
  5. Allayee H, Roth N, Hodis HN (2009) Polyunsaturated fatty acids and cardiovascular disease: implications for nutrigenetics. J Nutrigenet Nutrigenomics 2:140-48 CrossRef
  6. Nagai T, Anzai T, Mano Y, Kaneko H, Anzai A, Sugano Y, Maekawa Y, Takahashi T, Yoshikawa T, Fukuda K (2012) Eicosapentaenoic acid suppresses adverse effects of C-reactive protein overexpression on pressure overload-induced cardiac remodeling. Heart Vessels. doi:10.1007/s00380-012-0270-5
  7. Tomita T, Hata T, Takeuchi T, Oguchi Y, Okada A, Aizawa K, Koshikawa M, Otagiri K, Motoki H, Kasai H, Izawa A, Koyama J, Hongo M, Ikeda U (2012) High concentrations of omega-3 fatty acids are associated with the development of atrial fibrillation in the Japanese population. Heart Vessels. doi:10.1007/s00380-012-0264-3
  8. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y, Investigators J (2009) Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J 73:1283-290 CrossRef
  9. Ross R (1999) Atherosclerosis–an inflammatory disease. N Engl J Med 340:115-26 CrossRef
  10. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347:1557-565 CrossRef
  11. Ridker PM (2003) Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation 107:363-69 CrossRef
  12. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, Goto S, Liau CS, Richard AJ, Rother J, Wilson PW (2006) International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295:180-89 CrossRef
  13. Criqui MH, Denenberg JO, Langer RD, Fronek A (1997) The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med 2:221-26
  14. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE (1998) Peripheral arterial disease in the elderly: the Rotterdam study. Arterioscler Thromb Vasc Biol 18:185-92 CrossRef
  15. Guo X, Li J, Pang W, Zhao M, Luo Y, Sun Y, Hu D (2008) Sensitivity and specificity of ankle–brachial index for detecting angiographic stenosis of peripheral arteries. Circ J 72:605-10 CrossRef
  16. Ankle Brachial Index C, Fowkes FG, Murray GD, Butcher I, Heald CL, Lee RJ, Chambless LE, Folsom AR, Hirsch AT, Dramaix M, deBacker G, Wautrecht JC, Kornitzer M, Newman AB, Cushman M, Sutton-Tyrrell K, Fowkes FG, Lee AJ, Price JF, d’Agostino RB, Murabito JM, Norman PE, Jamrozik K, Curb JD, Masaki KH, Rodriguez BL, Dekker JM, Bouter LM, Heine RJ, Nijpels G, Stehouwer CD, Ferrucci L, McDermott MM, Stoffers HE, Hooi JD, Knottnerus JA, Ogren M, Hedblad B, Witteman JC, Breteler MM, Hunink MG, Hofman A, Criqui MH, Langer RD, Fronek A, Hiatt WR, Hamman R, Resnick HE, Guralnik J, McDermott MM (2008) Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300:197-08 CrossRef
  17. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, Group TIW (2007) Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45 Suppl S: S5-7
  18. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982-92 CrossRef
  19. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU (2011) The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 80:17-8 CrossRef
  20. Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S (2002) Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pac J Clin Nutr 11(Suppl 8):S732–S737 CrossRef
  21. Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148:839-43
  22. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, Krook SH, Hunninghake DB, Comerota AJ, Walsh ME, McDermott MM, Hiatt WR (2001) Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 286:1317-324 CrossRef
  23. Kurisu S, Ishibashi K, Kato Y, Mitsuba N, Dohi Y, Nishioka K, Kihara Y (2013) Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease. Heart Vessels 28:34-8 CrossRef
  24. Pasceri V, Willerson JT, Yeh ET (2000) Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102:2165-168 CrossRef
  25. Pearson TA, Mensah GA, Hong Y, Smith SC Jr (2004) CDC/AHA Workshop on Inflammatory Markers and Cardiovascular Disease. Application to clinical and public health practice: overview. Circulation 110:e543–e544 CrossRef
  26. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG (2005) C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh artery study. Circulation 112:976-83 CrossRef
  27. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJ, Gudmundsen O, Vige R, Payne SP, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC (2010) Eicosapentaenoic acid (EPA) from highly concentrated / n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis 212:252-59 CrossRef
  28. Hayakawa S, Yoshikawa D, Ishii H, Tanaka M, Kumagai S, Matsumoto M, Hayashi M, Sugiura T, Hayashi K, Ando H, Amano T, Murohara T (2012) Association of plasma omega-3 to omega-6 polyunsaturated fatty acid ratio with complexity of coronary artery lesion. Intern Med 51:1009-014 CrossRef
  29. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, Allison TG, Mookadam F, Lopez-Jimenez F (2006) Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 368:666-78 CrossRef
  30. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-34 CrossRef
  31. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM (1989) Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 2:757-61 CrossRef
  32. Gruppo italiano per lo studio della sopravvivenza nell’infarto miocardico (1999) Dietary supplementation with / n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: results of the GISSI–Prevenzione trial. Lancet 354:447-55 CrossRef
  33. Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, Zotos PC, Haboubi NA, Elwood PC (2003) Lack of benefit of dietary advice to men with angina: results of a controlled trial. Eur J Clin Nutr 57:193-00 CrossRef
  34. von Schacky C, Harris WS (2007) Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res 73:310-15 CrossRef
  
• 作者单位：Tsuyoshi Sugiura (1)
  Daiji Yoshikawa (2)
  Hideki Ishii (2)
  Susumu Suzuki (2)
  Soichiro Kumagai (2)
  Yosuke Inoue (2)
  Satoshi Okumura (2)
  Satoshi Isobe (2)
  Mutsuharu Hayashi (2)
  Hirohiko Ando (3)
  Tetsuya Amano (3)
  Toyoaki Murohara (2)
  
  1. Department of Cardiology, Ichinomiya Municipal Hospital, Ichinomiya, Japan
  2. Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan
  3. Department of Cardiology, Aichi Medical University, Nagakute, Japan
  
• ISSN：1615-2573

文摘

Eicosapentaenoic acid (EPA), a member of the omega-3 polyunsaturated fatty acid family, prevents cardiovascular disease. C-reactive protein (CRP) is a marker of inflammation, which promotes atherosclerosis. The aim of this study was to investigate the relationship among EPA, CRP, and the prevalence of peripheral artery disease (PAD), which is a manifestation of systemic atherosclerosis. A cross-sectional study was performed on 238 patients with coronary artery disease (CAD). Blood EPA and CRP levels and ankle-brachial pressure indices were measured. Cut-off values for plasma EPA levels and serum CRP levels were determined using receiver operating characteristic (ROC) analysis. Patients with ABIs??.9 were defined as having PAD. EPA levels were significantly lower and CRP levels were significantly higher in patients with PAD than in those without [48 (26-7) vs. 58 (41-3) μg/ml, p?=?0.026 and 3.3 (0.64-4.0) vs. 0.70 (0.32, 2.4) mg/l, p?=?0.004]. Multivariate analysis for PAD revealed that high CRP levels and low EPA levels were significant and independent predictors of PAD [odds ratio 3.1 (95?% CI 1.4-.9), p?=?0.006 and odds ratio 4.9 (95?% CI 1.5-.7), p?=?0.004]. Furthermore, to predict PAD, adding high CRP levels and low EPA levels to the established risk factors significantly improved the area under the ROC curves, from 0.66 to 0.78, of the PAD prediction model (p?=?0.004). A significant relationship among EPA, CRP, and PAD was confirmed in patients with CAD.